A randomized, placebo-controlled trial of bronchodilators for bronchoscopy in patients with COPD
dc.contributor.author | Stolz, Daiana | |
dc.contributor.author | Pollak, Vincent | |
dc.contributor.author | Chhajed, Prashant N. | |
dc.contributor.author | Gysin, Christian | |
dc.contributor.author | Pflimlin, Eric | |
dc.contributor.author | Tamm, Michael | |
dc.date | 2022-08-11T08:09:32.000 | |
dc.date.accessioned | 2022-08-23T16:34:39Z | |
dc.date.available | 2022-08-23T16:34:39Z | |
dc.date.issued | 2007-03-16 | |
dc.date.submitted | 2009-03-16 | |
dc.identifier.citation | Chest. 2007 Mar;131(3):765-72. <a href="http://dx.doi.org/10.1378/chest.06-2308">Link to article on publisher's site</a> | |
dc.identifier.issn | 0012-3692 (Print) | |
dc.identifier.doi | 10.1378/chest.06-2308 | |
dc.identifier.pmid | 17356091 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/38382 | |
dc.description.abstract | BACKGROUND: In contrast to asthma, the indication for bronchodilators prior to bronchoscopy in patients with COPD has not been properly investigated. We therefore performed a randomized, double-blind, placebo-controlled trial to determine whether use of a short-acting bronchodilator provides a protective effect in patients with COPD undergoing bronchoscopy. METHODS: One hundred twenty patients undergoing bronchoscopy were included. Patients with COPD were randomized to receive either 200 mug of salbutamol (n = 40) or placebo (n = 40) before bronchoscopy. Control patients (n = 40) did not receive any inhaled medication. Spirometry was performed before and 2 h after bronchoscopy in all patients. Sedative drug requirements and hemodynamic parameters were recorded. RESULTS: Hemodynamic findings before, during, and after bronchoscopy were similar in patients with COPD randomized to either salbutamol or placebo (p = not significant for all). Compared to prebronchoscopy values, postbronchoscopy percentage of predicted FEV(1) decreased significantly in all three groups: salbutamol (median, - 4.7%; interquartile range [IQR], - 13.3 to 6.6); placebo (median, - 4.8%; IQR, - 19.9 to 8.4); and control subjects (median, - 10.0%; IQR, - 20.2 to - 3.3) [p = 0.023]. The decrease in FEV(1) was similar in all three patient groups (p = 0.432). The relative change in FEV(1) was inversely correlated to the increasing severity of COPD as expressed by Global Initiative for Chronic Obstructive Lung Disease stages (p = 0.01). CONCLUSIONS: Premedication with an inhaled short-acting beta-agonist cannot be recommended in patients with COPD undergoing bronchoscopy. | |
dc.language.iso | en_US | |
dc.relation | <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=17356091&dopt=Abstract">Link to Article in PubMed</a> | |
dc.relation.url | http://dx.doi.org/10.1378/chest.06-2308 | |
dc.subject | Administration, Inhalation | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Aged, 80 and over | |
dc.subject | Albuterol | |
dc.subject | Bronchodilator Agents | |
dc.subject | *Bronchoscopy | |
dc.subject | Double-Blind Method | |
dc.subject | Female | |
dc.subject | Forced Expiratory Volume | |
dc.subject | Humans | |
dc.subject | Male | |
dc.subject | Middle Aged | |
dc.subject | Premedication | |
dc.subject | Pulmonary Disease, Chronic Obstructive | |
dc.subject | Statistics as Topic | |
dc.subject | Vital Capacity | |
dc.subject | Life Sciences | |
dc.subject | Medicine and Health Sciences | |
dc.title | A randomized, placebo-controlled trial of bronchodilators for bronchoscopy in patients with COPD | |
dc.type | Journal Article | |
dc.source.journaltitle | Chest | |
dc.source.volume | 131 | |
dc.source.issue | 3 | |
dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/oapubs/1248 | |
dc.identifier.contextkey | 782915 | |
html.description.abstract | <p>BACKGROUND: In contrast to asthma, the indication for bronchodilators prior to bronchoscopy in patients with COPD has not been properly investigated. We therefore performed a randomized, double-blind, placebo-controlled trial to determine whether use of a short-acting bronchodilator provides a protective effect in patients with COPD undergoing bronchoscopy. METHODS: One hundred twenty patients undergoing bronchoscopy were included. Patients with COPD were randomized to receive either 200 mug of salbutamol (n = 40) or placebo (n = 40) before bronchoscopy. Control patients (n = 40) did not receive any inhaled medication. Spirometry was performed before and 2 h after bronchoscopy in all patients. Sedative drug requirements and hemodynamic parameters were recorded. RESULTS: Hemodynamic findings before, during, and after bronchoscopy were similar in patients with COPD randomized to either salbutamol or placebo (p = not significant for all). Compared to prebronchoscopy values, postbronchoscopy percentage of predicted FEV(1) decreased significantly in all three groups: salbutamol (median, - 4.7%; interquartile range [IQR], - 13.3 to 6.6); placebo (median, - 4.8%; IQR, - 19.9 to 8.4); and control subjects (median, - 10.0%; IQR, - 20.2 to - 3.3) [p = 0.023]. The decrease in FEV(1) was similar in all three patient groups (p = 0.432). The relative change in FEV(1) was inversely correlated to the increasing severity of COPD as expressed by Global Initiative for Chronic Obstructive Lung Disease stages (p = 0.01). CONCLUSIONS: Premedication with an inhaled short-acting beta-agonist cannot be recommended in patients with COPD undergoing bronchoscopy.</p> | |
dc.identifier.submissionpath | oapubs/1248 | |
dc.contributor.department | Department of Pulmonary, Allergy and Critical Care Medicine | |
dc.source.pages | 765-72 |